Back grey_arrow_rt.gif
 
 
Trimeris Announces Appointment of Neil Graham, M.D., as Chief Medical Officer and Senior Vice President of Clinical Development and Medical Affairs
 
 
  MORRISVILLE, N.C.--(BUSINESS WIRE)----Trimeris, Inc. (NASDAQ:TRMS), a global leader in novel HIV therapeutics, today announced the appointment of Neil Graham, M.D., as Chief Medical Officer and Senior Vice President of Clinical Development and Medical Affairs. Dr. Graham will be responsible for directing all clinical development and medical affairs activities and will play a vital role in supporting FUZEON(R) (enfuvirtide) in the marketplace, as well as providing stewardship of pipeline development programs. Lynn Smiley, M.D., formerly Senior Vice President of Clinical Research, will assume the role of Senior Vice President of Regulatory Affairs, Compliance, and Drug Safety.
 
"Dr. Graham brings a superb reputation and an outstanding profile of experience in all phases of anti-viral drug development, and we are very excited to have someone of his caliber join the executive team of Trimeris," said Steven D. Skolsky, Chief Executive Officer of Trimeris.
 
Dr. Graham previously served as Chief Medical Officer for XTL Biopharmaceuticals Ltd. where he developed, planned and executed clinical development strategies and served as project leader for the hepatitis B and C clinical development programs. Prior to XTL, Dr. Graham was Vice President, Clinical Research and Medical Affairs with Tibotec-Virco NV, a subsidiary of Johnson and Johnson, overseeing the development of their HIV portfolio. Earlier in his career, Dr. Graham worked at Glaxo Wellcome Inc., now GlaxoSmithKline, as Director of HIV Programs and was the US strategic leader on the global HIV Therapeutic Area management team and co-leader of the US HIV Business Team. While at Glaxo Wellcome, Dr. Graham was involved in designing and implementing clinical trials for their entire portfolio of HIV products.
 
Dr. Graham attended the University of Adelaide in Australia where he received M.B.B.S., M.D. and Master of Public Health degrees. Later, at the Johns Hopkins University Schools of Medicine and Hygiene and Public Health, Dr. Graham's academic career concentrated on HIV, TB and hepatitis epidemiology research and teaching. While at Johns Hopkins, Dr. Graham treated HIV infected patients and his research became increasingly focused on HIV.
 
About Trimeris, Inc.
 
Trimeris, Inc. (Nasdaq:TRMS) is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. FUZEON, approved in the U.S., Canada and European Union, is the first in a new class of anti-HIV drugs called fusion inhibitors. Trimeris is developing FUZEON and future generations of peptide fusion inhibitors in collaboration with F. Hoffmann-La Roche Ltd. For more information about Trimeris, please visit the Company's website at http://www.trimeris.com.
 
Trimeris Safe Harbor Statement
 
This document and any attachments may contain forward-looking information about the Company's financial results and business prospects that involve substantial risks and uncertainties. These statements can be identified by the fact that they use words such as "expect," "project," "intend," "plan," "believe" and other words and terms of similar meaning. Among the factors that could cause actual results to differ materially are the following: there is uncertainty regarding the success of research and development activities, regulatory authorizations and product commercializations; the results of our previous clinical trials are not necessarily indicative of future clinical trials; and our drug candidates are based upon novel technology, are difficult and expensive to manufacture and may cause unexpected side effects. For a detailed description of these factors, see Trimeris' Form 10-K filed with the Securities and Exchange Commission on March 11, 2005 and its periodic reports filed with the SEC.
 
Trimeris, Inc. Bethany Greer, 919-419-6050
 
06/16/2005 07:30 ET
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org